Please login to the form below

Not currently logged in
Email:
Password:

bapineuzumab

This page shows the latest bapineuzumab news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

BACE inhibitors are designed to block the formation of the amyloid plaques that characterise the disease, unlike earlier antibody drugs such as Lilly’s solanezumab and Pfizer’s bapineuzumab which attempted

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Work on Pfizer, J&J and Elan's bapineuzumab, Lundbeck/Myriad Genetics' Flurizan, Pfizer and Medivation's Dimebon (latrepirdine), to name a few, has come to a halt in recent years.

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    And despite recent disappointments involving Alzheimer's candidate bapineuzumab, the company is still committed to tackling the “huge unmet medical need” of the condition, according to Rodriguez.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics